ErbB2 growth factor receptor, a marker for neuroendocrine cells?

Pancreatology

Volumn 5, Issue 1, 2005, Pages 44-58

  Standop, Jens ^a,c   Andrianifahanana, Mahefatiana ^b   Moniaux, Nicolas ^b   Schneider, Matthias ^a   Ulrich, Alexis ^a,d   Brand, Randall E ^a   Wisecarver, James L ^b   Bridge, Julia A ^b   Büchler, Markus W ^d   Adrian, Thomas E ^e   Batra, Surinder K ^b   Pour, Parviz M ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF BONN   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Adrenal gland; CNS; ErbB2 growth factor receptor; Ganglia; Islets of langerhans; Neuroendocrine cells; Pancreas

Indexed keywords

CELL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADOLESCENT; ADULT; AGED; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL; CELL HETEROGENEITY; CELL TYPE; CHILD; CHRONIC PANCREATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GANGLION; GENE OVEREXPRESSION; HAMSTER; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LANGERHANS CELL; MALE; METASTASIS; NEUROSECRETORY CELL; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS ISLET CELL; PRIORITY JOURNAL; SPECIES DIFFERENCE;

EID: 21044445280     PISSN: 14243903     EISSN: 14243911     Source Type: Journal    
DOI: 10.1159/000084490     Document Type: Article

References (60)

1. Ozawa F, Friess H, Tempia-Caliera A, Kleeff J, Büchler MW: Growth factors and their receptors in pancreatic cancer. Teratog Carcinog Mutagen 2001;21:27-44.
2. Piccart MJ, Awada A: State-of-the-art chemotherapy for advanced breast cancer. Semin Oncol 2000;27(suppl 9):3-12.
3. Koeppen HKW, Wright BD, Burt AD, Quirke P, McNicol AM, Dybdal NO, Sliwkowski AX, Hillan KJ: Overexpression of HER2/neu in solid tumors: An immunohistochemical survey. Histopathology 2001;38:96-104.
4. Apple SK, Hecht JR, Lewin DN, Jahromi SA, Grody WW, Nieberg RK: Immunohistochemical evaluation of K-raps, p53, and HER-2/neu expression in hyperplastic, dysplastic, and carcinomatous lesions of the pancreas: Evidence for multistep carcinogenesis. Hum Pathol 1999;30:123-129.
5. Day JD, Digiuseppe JA, Yeo C, Lai-Goldman M, Anderson SM, Goodman SN, Kern SE, Hruban RH: Immunohistochemical evaluation of HER-2/neu expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms. Hum Pathol 1996;27:119-124.
6. Hall PA, Hughes CM, Staddon SL, Richman PI, Gullick WJ, Lemoine NR: The c-erb B-2 proto-oncogene in human pancreatic cancer. J Pathol 1990;161:195-200.
7. Lei S, Appert HE, Nakata B, Domenico DR, Kim K, Howard JM: Overexpression of HER2/neu oncogene in pancreatic cancer correlates with shortened survival. Int J Pancreatol 1995; 17:15-21.
8. Satoh K, Sasano H, Shimosegawa T, Koizumi M, Yamazaki T, Mochizuki F, Kobayashi N, Okano T, Toyota T, Sawai T: An immunohistochemical study of the c-erbB-2 oncogene product in intraductal mucin-hypersecreting neoplasms and in ductal cell carcinomas of the pancreas. Cancer 1993;72:51-56.
9. Dergham ST, Dugan MC, Arlauskas P, Du W, Vaitkevicius VK, Crissman JD, Sarkar FH: Relationship of family cancer history to the expression of p53, p21WAF-1, HER-2/neu, and K-ras mutation in pancreatic adenocarcinoma. Int J Pancreatol 1997;21:225-234.
10. Dugan MC, Dergham ST, Kucway R, Singh K, Biernat L, Du W, Vaitkevicius VK, Crissman JD, Sarkar FH: HER-2/neu expression in pancreatic adenocarcinoma: Relation to tumor differentiation and survival. Pancreas 1997;14: 229-236.
11. Friess H, Wang L, Zhu Z, Gerber R, Schroder M, Fukuda A, Zimmermann A, Korc M, Büchler MW: Growth factor receptors are differentially expressed in cancers of the papilla of Vater and pancreas. Ann Surg 1999;230:767-774.
12. Yamanaka Y, Friess H, Kobrin MS, Büchler M, Kunz J, Beger HG, Korc M: Overexpression of HER2/neu oncogene in human pancreatic carcinoma. Hum Pathol 1993;24:1127-1134.
13. Hall PA, Lemoine NR: Models of pancreatic cancer. Cancer Surv 1993;16:135-155.
14. Longnecker DS, Memoli V, Pettengill OS: Recent results in animal models of pancreatic carcinoma: Histogenesis of tumors. Yale J Biol Med 1992;65:457-464.
15. Pour P: Experimental pancreatic cancer. Am J Surg Pathol 1989;13(suppl 1):96-103.
16. Standop J, Schneider MB, Ulrich A, Pour PM: Experimental animal models in pancreatic carcinogenesis: Lessons for human pancreatic cancer. Dig Dis 2001;19:24-31.
17. Schmied B, Ulrich A, Matsuzaki H, Ding X, Ricordi C, Moyer M, Batra S, Adrian T, Pour P: Maintenance of human islets in long term culture. Differentiation 2000;66:173-180.
18. Pour PM, Kazakoff K, Dulaney K: A new multilabeling technique for simultaneous demonstration of different islet cells in permanent slides. Int J Pancreatol 1993;13:139-142.
19. Paik S, Burkhard E, Lippman ME: Clinical significance of erbB2 protein overexpression. Cancer Treat Res 1992;61:181-191.
20. Pour PM, Permert J, Mogaki M, Fujii H, Kazakoff K: Endocrine aspects of exocrine cancer of the pancreas. Their patterns and suggested biologic significance. Am J Clin Pathol 1993;100: 223-230.
21. Lofts FJ, Gullick WJ: c-erbB2 amplification and overexpression in human tumors. Cancer Treat Res 1992;61:161-179.
22. Olayioye MA, Neve RM, Lane HA, Hynes NE: The ErbB signaling network: receptor heterodimerization in development and cancer. Embo J 2000;19:3159-3167.
23. Nagy P, Jenei A, Damjanovich S, Jovin TM, Szolosi J: Complexity of signal transduction mediated by ErbB2:Clues to the potential of receptor-targeted cancer therapy. Pathol Oncol Res 1999;5:255-271.
24. Press M, Hung G, Godolphin W, Slamon D: Sensitivity of HER-2/neu antibodies in archival tissue samples: Potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 1994;54:2771-2777.
25. Kritzik MR, Krahl T, Good A, Gu D, Lai C, Fox H, Sarvetnick N: Expression of ErbB receptors during pancreatic islet development and regrowth. J Endocrinol 2000;165:67-77.
26. Sessa F, Solcia E, Capella C, Bonato M, Scarpa A, Zamboni G, Pellegata NS, Ranzani GN, Rickaert F, Kloppel G: Intraductal papillary-mucinous tumours represent a distinct group of pancreatic neoplasms: An investigation of tumour cell differentiation and K-ras, p53 and c-erbB-2 abnormalities in 26 patients. Virchows Arch 1994;425:357-367.
27. Ross JS, Sheehan C, Hayner-Buchan AM, Ambros RA, Kallakury BV, Kaufman R, Fisher HA, Muraca PJ: HER-2/neu gene amplification status in prostate cancer by fluorescence in situ hybridization. Hum Pathol 1997;28:827-833.
28. Quirke P, Pickles A, Tuzi N, Mohamdee O, Gullik W: Pattern of expression of c-erbB-2 oncoprotein in human fetuses. Br J Cancer 1989;60:64-69.
29. Cannella B, Pitt D, Marchionni M, Raine CS: Neuregulin and erbB receptor expression in normal and diseased human white matter. J Neuroimmunol 1999;100:233-242.
30. Garratt AN, Voiculescu O, Topilko P, Charnay P, Birchmeier C: A dual role of erbB2 in myelination and in expansion of the Schwann cell precursor pool. J Cell Biol 2000;148:1035-1046.
31. Kokai Y, Cohen JA, Drebin JA, Greene MI: Stage- and tissue-specific expression of the neu oncogene in rat development. Proc Natl Acad Sci USA 1987;84:8498-8501.
32. Martin-Lacave I, Utrilla JC: Expression of a neu/c-erbB-2-like product in neuroendocrine cells of mammals. Histol Histopathol 2000;15: 1027-1033.
33. Graber HU, Friess H, Kaufmann B, Willi D, Zimmermann A, Korc M, Büchler MW: ErbB-4 mRNA expression is decreased in non-metastatic pancreatic cancer. Int J Cancer 1999;84:24-27.
34. Prigent SA, Lemoine NR, Hughes CM, Plowman GD, Selden C, Gullick WJ: Expression of the c-erbB-3 protein in normal human adult and fetal tissues. Oncogene 1992;7:1273-1278.
35. Carraway K III, Sweeney C: Localization and modulation of ErbB receptor tyrosine kinases. Current Opin Cell Biol 2001;13:125-130.
36. Mori S, Akiyama T, Morishita Y: Light and electron microscopical demonstration of c-erbB-2 gene product-like immunoreactivity in human malignant tumors. Virchows Arch B 1987;54:8-15.
37. Coombs L, Pigott D, Sweeney E, Proctor A, Eydmann M, Parkinson C, Knowles M: Amplification and overexpression of c-erbB-2 in transitional cell carcinoma of the urinary bladder. Br J Cancer 1991;63:601-606.
38. De Potter C, Van Daele S, Van de Vijer M, Pauwels C, Maertens G, De Boever J, Vandekerckhove D, Roels H: The expression of the neu oncogene product in breast lesions and in normal fetal and adult human tissues. Histopathology 1987;15:351-362.
39. Carraway KL 3rd, Rossi EA, Komatsu M, Price-Schiavi SA, Huang D, Guy PM, Carvajal ME, Fregien N, Carraway CA, Carraway KL: An intramembrane modulator of the ErbB2 receptor tyrosine kinase that potentiates neuregulin signaling. J Biol Chem 1999;274:5263-5266.
40. Carraway KL, Price-Schiavi SA, Komatsu M, Idris N, Perez A, Li P, Jepson S, Zhu X, Carvajal ME, Carraway CA: Multiple facets of sialomucin complex/MUC4, a membrane mucin and erbb2 ligand, in tumors and tissues (Y2K update). Front Biosci 2000;5:D95-D107.
41. Albanell J, Baselga J: The ErbB receptors as targets for breast cancer therapy. J Mammary Gland Biol Neoplasia 1999;4:337-351.
42. Groger G, Layer P: Exocrine pancreatic function in diabetes mellitus. Eur J Gastroenterol Hepatol 1995;7:740-746.
43. Schneider MB, Matsuzaki H, Haorah J, Ulrich A, Standop J, Ding XZ, Adrian TE, Pour PM: Prevention of pancreatic cancer induction in hamsters by metformin. Gastroenterology 2001;120:1263-1270.
44. Schmied BM, Ulrich A, Matsuzaki H, Li C, Friess H, Büchler MW, Andren-Sandberg A, Adrian T, Pour P: Alteration of the Langerhans islet in pancreatic cancer patients. Int J Pathol 2000;28:187-197.
45. Friess H, Berberat P, Schilling M, Kunz J, Korc M, Büchler MW: Pancreatic cancer: The potential clinical relevance of alterations in growth factors and their receptors. J Mol Med 1996;74:35-42.
46. Ouyang X, Gulliford T, Huang G, Epstein RJ: Transforming growth factor-α short-circuits downregulation of the epidermal growth factor receptor. J Cell Physiol 1999;179:52-57.
47. Worthylake R, Opresko LK, Wiley HS: ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors. J Biol Chem 1999;274:8865-8874.
48. D'Souza B, Taylor-Papadimitriou J: Overexpression of ERBB2 in human mammary epithelial cells signals inhibition of transcription of the E-cadherin gene. Proc Natl Acad Sci USA 1994;91:7202-7206.
49. Petit AM, Rak J, Hung MC, Rockwell P, Goldstein N, Fendly B, Kerbel RS: Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases downregulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 1997;151:1523-1530.
50. Bourguignon LY, Zhu H, Chu A, Iida N, Zhang L, Hung MC: Interaction between the adhesion receptor, CD44, and the oncogene product, p185HER2, promotes human ovarian tumor cell activation. J Biol Chem 1997;272:27913-27918.
51. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J: Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 1998;58:2825-2831.
52. Pietras RJ, Fendly BM, Chazin VR, Pegram MD, Howell SB, Slamon DJ: Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 1994;9:1829-1838.
53. Büchler P, Reber HA, Büchler MC, Roth MA, Büchler MW, Friess H, Isacoff WH, Hines OJ: Therapy for pancreatic cancer with a recombinant humanized anti-HER2 antibody (Herceptin). J Gastrointest Surg 2001;5:139-146.
54. Safran H, Ramanathan RK, Schwartz J: Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Proc Am Soc Clin Oncol 2001;20:A517.
55. Ewer MS, Gibbs HR, Swafford J, Benjamin RS: Cardiotoxicity in patients receiving transtuzumab (Herceptin): primary toxicity, synergistic or sequential stress, or surveillance artifact? Semin Oncol 1999;26(4 suppl 12):96-101.
56. Lloyd RV: Immunohistochemical localization of chromogranin in normal and neoplastic endocrine tissues. Pathol Annu 1987;22:69-90.
57. Press MF, Cordon-Cardo C, Slamon DJ: Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 1990;5:953-962.
58. LeBras S, Czernichow P, Scharfmann R: A search for tyrosine kinase receptors expressed in the rat embryonic pancreas. Diabetologia 1998;41:1474-1481.
59. Pour PM, Weide L, Liu G, Kazakoff K, Scheetz M, Toshkov I, Ikematsu Y, Fienhold MA, Sanger W: Experimental evidence for the origin of ductal-type adenocarcinoma from the islets of Langerhans. Am J Pathol 1997;150:2167-2180.
60. Schneider M, Standop J, Ulrich A, Wittel U, Friess H, Andren-Sandberg A, Pour P: Expression of nerve growth factors in pancreatic neural tissue and pancreatic cancer. J Histochem Cytochem 2001;49:1205-1210.